Anatomy

Janacek’s Jenufa: an anatomy of anguish | Culture | The Sunday Times – The Times

Perhaps the most disappointing cancellation of the lockdown periods was Claus Guths new Royal Opera production of Janaceks Jenufa already well advanced in the rehearsal rooms last March with the mouthwatering cast of Asmik Grigorian, her RO debut, and Karita Mattila in the leading female roles of Jenufa and her stepmother, Kostelnicka Buryova.

Compensation of sorts came last weekend, when Simon Rattle raised his baton at Berlins Staatsoper Daniel Barenboims opera house to conduct Damiano Michielettos new production, socially distanced on stage and closed to the public, with the Finnish soprano Camilla Nylund as the secretly pregnant heroine, and Evelyn Herlitzius as the infanticidal matriarch who kills her stepdaughters baby to protect her own and Jenufas reputation.

The opera, premiered in

Originally posted here:
Janacek's Jenufa: an anatomy of anguish | Culture | The Sunday Times - The Times

Anatomy

Anatomy of… Katherine Brunt | Sport | The Sunday Times – The Times

FactfileAge 35Height 5ft 4inODIs 116IT20s 88ICC womens ODI bowling ranking 11 (Highest ranking: 1, 2013)ICC womens IT20 bowling ranking 12 (Highest ranking: 1, 2010)

Right armIn her first Test against New Zealand in 2004, when she was 19 years old, her first wicket was Rebecca Rolls, regarded as one of the best batters in the world at the time. Brunt is now Englands leading all-time wicket taker. In recent years she has also developed her batting talent. She credits the former England Women head coach Mark Robinson with this success: Its really been [him] seeing the batsman in me, she told ESPN Cricinfo in 2019. Hes honed me to get the batsman out of me, giving me the

Original post:
Anatomy of... Katherine Brunt | Sport | The Sunday Times - The Times

Anatomy

Nikiea Redmond and Kirsten DAndrea Hollander Discuss Their 10-Year Documentary with Anatomy of Wings | Slamdance 2021 [Exclusive Interview] – LRM…

Nikiea Redmond and Kirsten DAndrea Hollander directedAnatomy of Wings.

Anatomy of Wings is a ten-year journey for many participants in the documentary.

The film started off as a small film project for young children ended to be a coming-of-age documentary of ten young girls for half their lives under a mentorship program in Baltimore.

Heres the synopsis:

At first, gathered to create an after-school film project, ten Black middle school girls return each week to collaborate with their Black and white mentors on a feature-length documentary about their own coming-of-age in Baltimore City. Weeks turn into years. Then, shortly before the girls high school graduation, a sea of misunderstanding arises about whats to come. The self-defined second family is left to question if their solidarity will survive the realities of living in a world of racial inequity.

It all started out at Dunbar Middle School, where mentors Nikiea Redmond and Kirsten DAndrea Hollander kickstarted an afternoon weekly program called Wings. Initially created for young girls in middle school to learn about video skills, the formal curriculum quickly starts to fade away and the weekly meetings organically begin to shift towards discussing the vulnerabilities of the girls experiences. Through trust, mentorship, and leaps of faith, a deep bond is created with the girls that last the test of time. What was only intended to be a 10-week course ends turning into a 10+ year experience, where the girls are cinematographers with autonomy in framing how their stories are shared with the world.

The ten young women being mentored, included Brittany Backmon, Teshavionna Tazz Mitchell, Shelia Butler, Brienna Brown, Marquise Weems, Danisha Harris, Cami McCrief, Quandra Jones, Tywana Reid, and Quanisha Carmichael. The Wings mentors included Kirsten DAndrea Hollander, Jackie Duvall-Harvery, Jane Cottis, Nikiea Redmond, Kata Frederick, and Cinnamon Triano.

LRMs Gig Patta discussed with co-directors Nikiea Redmond and Kirsten DAndrea Hollander regards to the 10-year documentary of their own lives.

Nikiea Redmond received her bachelors in corporate communications from the University of Baltimore in 2011. Redmond serves as a liaison for political organizations and community groups in East Baltimore. In 2004, she received the Sam Lacy Award for Youth Leadership from The Afro-American Newspaper. The following year, she was the 2015 recipient of the Black Wall Street Journal Award for her work in Baltimore City.

Kirsten DAndrea Hollander is a full-time professor at the Maryland Institute College of Art (MICA, where she directs the MFA Filmmaking program. In 2008, she launched the Wings Video Skills After School Program for Girls, which lead to this documentary. In 2011, she was selected to the Independent Filmmaker Project Fellowship to launch her first feature-length documentary Us, Naked: Trixie & Monkey.

Anatomy of Wings documentary currently streams at the Slamdance Film Festival. Visit http://www.slamdance.com for ticket information.

Watch the exclusive interview below. Let us know what you think.

Source: LRM Online Exclusive, Raw Honey Films

Read more from the original source:
Nikiea Redmond and Kirsten DAndrea Hollander Discuss Their 10-Year Documentary with Anatomy of Wings | Slamdance 2021 [Exclusive Interview] - LRM...

Biochemistry

The future of science education: Q&A with the creator of a new chemistry course – Arizona Daily Wildcat

Laura Van Dorn is a professor at the University of Arizona. She currently teaches chemistry 101A and 101B. CHEM 101A is a general chemistry course and CHEM 101B is an introductory course to organic chemistry and biochemistry. Due to the pandemic, both classes have been switched to a live-online format.

Van Dorn has developed a new, challenging chemistry course: CHEM 130. It is designed to have a year's worth of general chemistry completed in a single semester. CHEM 130 is for students who need the foundations of chemistry and biochemistry, but given their career focus in different areas, will not necessarily go on to take additional chemistry classes. The Daily Wildcat sat down with Van Dorn via email to find out more about the process of starting a new course.

Daily Wildcat: Can you provide a brief description of CHEM 130?

Laura Van Dorn: CHEM 130 will introduce students in nursing and public health majors to the fundamental principles of general and organic chemistry and elements of biochemistry, with a focus on medical, nutritional, and environmental aspects of the discipline.

Current topics in health sciences will be used to guide students in developing a solid background in chemistry that may be applied in their future careers. Critical thinking and pattern recognition will be utilized with the goal of developing skills in problem-solving, applying the foundations of chemistry to new concepts.

Students will be taught to integrate their conceptual and modeling skills with quantitative data to make predictions regarding the behavior of molecules in different environments.

DW: What makes CHEM 130 different from other entry-level chemistry courses?

Van Dorn: CHEM 130 is a one-semester overview of the material, which other chemistry and biochemistry courses typically take several semesters to cover. It is the only course of this kind at UArizona.

It is designed for students who need a fundamental understanding of chemistry and biochemistry, but do not have room in their degree programs for the traditional 2 semesters of General chemistry, two semesters of Organic Chemistry, and two semesters of Biochemistry (which is what Chemistry or Biochemistry majors would normally take).

CHEM 130 will emphasize the elements of chemistry and biochemistry important to public health and nursing fields. It will introduce students to recognizing patterns and making predictions. Demonstrations and activities will be a large part of the course. It can be difficult to visualize some of the concepts in chemistry, thus being able to see the effects of chemicals on different types of matter has the tendency to help students.

DW: Do you recommend those only in the pre-health route to take CHEM 130?

Van Dorn: No, this course is for anyone with an interest in how chemistry applies to every aspect of our lives. Our bodies, our environment, all of it is chemistry.

DW: How would you describe the rigor of this course?

Van Dorn: CHEM 130 will be a challenging class, preparing students for careers in health-related fields. Although no extensive background in math or science will be required before taking the class, students should expect to invest considerable effort in mastering the material. Readings will be assigned before class, and students will complete weekly homework as well as unit assessments.

As the course will be offered in-person and through Arizona Online, students will be able to complete much of the course at their own pace. A three-unit science course does require time outside class, and motivation on the part of the students, but theyll learn some really interesting things.

DW: Is CHEM 130 going to be offered as an alternative for CHEM 151?

Van Dorn: CHEM 130 will be very different from CHEM 151 or its equivalent CHEM 141. CHEM 141 or 151 covers only the first half of General Chemistry. CHEM 130 will encompass all of General Chemistry (i.e. CHEM 141/151 plus CHEM 142/152), in addition to important elements of Organic Chemistry and Biochemistry.

The depths of coverage will, of course, be different, given the course objectives, its target audience, and time constraints, but it is important to stress that CHEM 130 is a much broader class than either CHEM 141 or CHEM 151. CHEM 141 or 151 are suitable for students that need chemistry as a prerequisite for higher-level chemistry classes and have a foundation in math.

DW: Is there anyone else you made and/or designed the class with?

Van Dorn: The course content is my own. I will be working with Celeste Atkins at Arizona Online in order to offer the class online as well as in-person for Fall 2021. Colleen Kelly will be developing the separate lab course, CHEM 130L.

Follow Briana Aguilar on Twitter

Let us come to you. The Daily Wildcat, straight to your inbox. News. Science/Health. Sports. Arts/Lifestyle. You choose. You cancel at any time.

See more here:
The future of science education: Q&A with the creator of a new chemistry course - Arizona Daily Wildcat

Biochemistry

UW chemist and oceanographer named Sloan Fellows – UW News

News releases

February 16, 2021

Two faculty members at the University of Washington have been awarded early-career fellowships from the Alfred P. Sloan Foundation. The new Sloan Fellows, announced Feb. 16, areAshleigh Theberge, an assistant professor in the Department of Chemistry and Jodi Young, an assistant professor in the School of Oceanography.

Open to scholars in eight scientific and technical fields chemistry, computer science, economics, mathematics, molecular biology, neuroscience, ocean sciences and physics the fellowships honor those early-career researchers whose achievements mark them among the next generation of scientific leaders.

The 128 Sloan Fellows for 2021 were selected in coordination with the research community. Candidates are nominated by their peers, and fellows are selected by independent panels of senior scholars based on each candidates research accomplishments, creativity and potential to become a leader in their field. Each fellow will receive $75,000 to apply toward research endeavors.

This years fellows come from 58 institutions across the United States and Canada, spanning fields from evolutionary biology to data science.

Ashleigh Theberge

Theberge is an assistant professor of chemistry. Her research probes the chemical signals that cells use to communicate with one another. The organization of our bodies, with different types of cells taking on discrete functions, depends on this biochemical language.

Were alive because our cells can exchange chemical messages in appropriate ways, said Theberge, who is also an adjunct assistant professor of urology at the UW. All cells human cells, microbes utilize chemical signals to deliver information and influence the properties of other cells.

Jodi Young

Youngis an assistant professor in the School of Oceanography. She studies microbial oceanography, with a focus on the role of marine algae in the carbon cycle. In particular, her research explores polar ecosystems and other extreme environments, and the biochemistry of photosynthesis. Herresearchcombines fieldwork,algal culture manipulationsand biochemical and molecular analyses to uncover the evolution and adaptations of biological carbon fixation in the oceans.

Half of all photosynthesis happens in the oceans, across an amazingly diverse collection of organisms, Young said. My groups research focuses on understanding the underlying physiological and molecular adaptations of marine photosynthesis. Understanding how marine algae have and will adapt to a changing climatereveals insights into how life on Earth evolved and will respond in the future.

For more information, contact Theberge atabt1@uw.edu and Young at youngjn@uw.edu.

Originally posted here:
UW chemist and oceanographer named Sloan Fellows - UW News

Biochemistry

Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing…

NEW YORK, Feb. 18, 2021 /PRNewswire/ --Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced positive top-line data from an investigator-sponsored phase 2 proof-of-concept clinical trial of IMU-838 in primary sclerosing cholangitis (PSC). This single-arm, open-label, exploratory study was designed to investigate IMU-838's potential to improve various biochemical parameters in PSC patients and help determine whether any such activity warrants further investigation in randomized PSC trials. As previously announced, due to the COVID-19 pandemic, only 18 of the targeted 30 patients were enrolled in the study (intent-to-treat population, ITT), of whom only 11 patients completed the full IMU-838 treatment course and were evaluable over the 24-week treatment period (per-protocol population, PP).

The PP population experienced a statistically significant decrease in serum alkaline phosphatase (ALP) levels (p=0.041) after 24 weeks of treatment using 30 mg IMU-838 once daily, as compared to baseline. A consistent individual pattern of a stable decrease in ALP values was observed in the PP population between baseline and week 24, without any single patient showing an increase of more than 20% of ALP. As per the definition of the primary objective of the study, 27.3% of the patients in the PP population had a clinically relevant reduction of serum ALP higher than 25% at week 24, without an increase in liver biochemistry of more than 33%, as compared to baseline. Biochemical endpoints, such as changes in serum ALP, have been used in PSC trials performed by third parties.

Regarding the secondary objectives of the study, no changes in aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total, direct or indirect bilirubin were observed in the ITT or PP populations, as compared to baseline. In addition, despite the limited scope of the data, encouraging results were observed regarding symptoms of inflammatory bowel disease, a common comorbidity for PSC patients, and patient assessments of health-related quality of life. The study also found that IMU-838 is a safe and well-tolerated oral drug for PSC patients and treatment-emergent adverse events were rare and generally mild.

"I am very excited about the effects we have seen in this highly underserved patient population where there is only a small number of cases worldwide and where no pharmaceutical treatment option is currently available," noted Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. "We are also very pleased to see that IMU-838's safety and tolerability profile was confirmed in this patient group. The results from this small, open-label study suggest that IMU-838 merits further clinical testing in PSC. We are in discussions with investigators and leading clinical experts to further evaluate the data set and to explore potential next steps for this indication."

"Currently, no effective treatment options are available for PSC patients and the hepatology community is very keen to see new approaches and clinical programs for the investigation of promising new approaches. I am grateful that Mayo Clinic and Immunic are collaboratively exploring this underserved indication for which liver transplantation is often the only effective option," stated Keith Lindor, M.D., Professor of Medicine Emeritus and former President of the American Association for the Study of Liver Diseases. "Although we are mindful of the small size of this dataset, I do believe the results are noteworthy and merit further exploration. Notable in this small patient cohort is the absolute consistency with which these patients experienced decreases in serum alkaline phosphatase at the 24-week time point."

Study Background and Baseline Characteristics

The single-arm, open label, exploratory study was an investigator-sponsored trial led by Elizabeth Carey, M.D., Professor of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, who had received Investigator Investigational New Drug (IND) approval from the U.S. Food & Drug Administration (FDA) and had been granted Institutional Review Board (IRB) approval to conduct the study. The study was supported by a grant from the National Institutes of Health (NIH) and was conducted at two sites: Mayo Clinic, Phoenix, Arizona (Dr. Carey) and Mayo Clinic, Rochester, Minnesota (John E. Eaton, M.D.), both of which are tertiary referral centers for PSC patients.

The study, for which Immunic provided the study medication, planned to enroll 30 patients with PSC, aged 18 to 75 years, who received 30 mg of IMU-838 once daily for a period of 24 weeks. Enrollment for the study took place between July 2019 and September 2020, but almost all enrollment occurred in 2019 and early 2020. During the COVID-19 pandemic, recruitment for this study was hampered, as patients with PSC are at a high risk of COVID-19 infections and were advised to avoid travel and unnecessary social contacts such as those required to participate in a clinical trial. Together with the investigators, Immunic determined to readout data of the 18 patients who were enrolled prior to the COVID-19 pandemic. The ongoing COVID-19 pandemic also triggered the principal investigator's decision to terminate the study in late 2020, before the intended recruitment goal of 30 patients was reached.

A total of 18 patients started treatment of 30 mg IMU-838 once daily (intent-to-treat population, ITT, n=18). Of these 18 patients, 11 patients received the full 24-week treatment with IMU-838 (per-protocol population, PP, n=11). Due to the high number of discontinued patients during the COVID-19 pandemic and the fact that all discontinued patients in an ITT statistical analysis will be counted as treatment failures at week 24, this analysis focuses mainly on the 11-patient PP population.

Primary Objective

The primary objective of this study was to determine whether IMU-838 reduces serum ALP in adult patients diagnosed with PSC. The main analysis for the primary objective was whether patients could achieve a reduction of ALP at week 24 which is greater or equal to 25%, as compared to baseline, while the AST increase at week 24 is no more than 33%, as compared to baseline. This positive primary outcome was achieved by 3 of 11 patients in the PP population (27.3%, 95% CI: 6-61%). By virtue of inclusion criteria, patients at baseline had to have an elevated ALP value of at least 1.5 times upper limit of normal (ULN).

In addition, time from baseline was calculated as a continuous variable and treated as the primary predictor using a random intercept model which was adjusted for age at baseline and gender. For this longitudinal analysis of ALP from baseline to week 24 in the PP population, the ALP value statistically significantly (p=0.041) decreased by an average of 5.76 IU/L every 30 days (95% CI: -11.29, -0.23; statistical model). The time trend was not statistically significant in the ITT analysis (p=0.578) due to missing data following the high rate of treatment discontinuations during the COVID-19 pandemic.

Secondary Objectives

Secondary objectives were to investigate the liver biochemistry parameters, AST, ALT, and total/direct/indirect bilirubin, as well as the concentrations of proinflammatory cytokines, as compared to baseline. The longitudinal analysis of both AST and ALT as well as total, direct and indirect bilirubin values showed a stable pattern in the PP population with no statistically significant change over time and the confidence interval to include the no-change scenario (AST: average 30 day change 1.22 IU/L, 95% CI: -0.53, 2.97, p=0.170; ALT: average 30 day change 0.85 IU/L, 95% CI -1.46, 3.15, p=0.467, total bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.02, p=0.561, direct bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.01, p=0.861, indirect bilirubin: average 30 day change 0.00 mg/dL, 95% CI -0.01, 0.01, p=0.556). Similar results were found in the ITT population. In addition, a decrease in the Ulcerative Colitis Clinical score was observed in evaluated patients, although the number of assessed patients was limited.

"This was a feasibility study to explore activity of IMU-838 in PSC patients based on biochemical parameters. IMU-838 was found to lead to a statistically significant reduction of serum ALP over time in the PP population, while no trend for increases in ALT, AST or bilirubin was observed," commented Andreas Muehler, M.D., Chief Medical Officer of Immunic. "Despite the challenges we faced due to COVID-19, which severely hindered the enrollment at the two Mayo Clinic sites and which led to an unusually high discontinuation rate and an early termination of the study, we have seen encouraging activity signals for IMU-838 in this patient population. Based on these promising data and, in particular, the improvement in biochemical liver parameters, we will continue to evaluate the potential of IMU-838 as a treatment option for PSC patients. It may also be worthwhile to optimize dose levels of IMU-838 in PSC patients in the future."

For more information on this clinical trial, please visit: http://www.clinicaltrials.gov, NCT03722576.

Conference Call and Webcast Information

As previously announced, Immunic's management team will host a public conference call and webcast today, February 18, 2021 at8:00 a.m. Eastern Timeto discuss the data from the main phase 2 analysis of the CALVID-1 trial of IMU-838 in hospitalized patients with moderate COVID-19, as well as data from the investigator-sponsored phase 2 clinical trial of IMU-838 in primary sclerosing cholangitis.

To participate in the conference call, dial 1-877-870-4263 (USA) or 1-412-317-0790 (International) and ask to be joined into the Immunic, Inc. call. A live, listen-only webcast of the conference call can be accessed at https://www.webcaster4.com/Webcast/Page/2301/39950or on the "Events and Presentations" section of Immunic's website at ir.imux.com/events-and-presentations.

An archived replay of conference call and webcast will be available approximately one hour after the completion for one year on Immunic's website at: ir.imux.com.

About Primary Sclerosing Cholangitis (PSC) PSC is a rare liver disease with a prevalence of approximately 4.15 per 100,000 in the United States, in which the bile ducts in the liver become inflamed, narrow and prevent bile from flowing properly. The exact cause and disease mechanism of PSC are still unknown, but an autoimmune mechanism may play a role. There is an association with inflammatory bowel diseases, most often with ulcerative colitis and less commonly with Crohn's disease. PSC is a progressive disease and, other than liver transplantation, there are currently no approved therapies that have been shown to improve survival in patients with PSC. The estimated time from diagnosis of PSC to death or liver transplant has been shown to be less than 15 years.

About IMU-838IMU-838 is an orally available, next-generation selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase (DHODH). IMU-838 acts on activated T and B cells while leaving other immune cells largely unaffected and allows the immune system to stay functioning, e.g. in fighting infections. In previous trials, IMU-838 did not show an increased rate of infections compared to placebo. In addition, DHODH inhibitors, such as IMU-838, are known to possess a host-based antiviral effect, which is independent with respect to specific virus proteins and their structure. Therefore, DHODH inhibition may be broadly applicable against multiple viruses. IMU-838 was successfully tested in two phase 1 clinical trials in 2017 and is currently being tested in a phase 2 trial in patients with ulcerative colitis. In the third quarter of 2020, the company reported positive results from its phase 2 EMPhASIS trial of IMU-838 in relapsing-remitting multiple sclerosis, achieving both primary and key secondary endpoints with high statistical significance. In the first quarter of 2021, Immunic announced that IMU-838 has shown evidence of clinical activity in its phase 2 CALVID-1 trial in hospitalized patients with moderate COVID-19. Also, in the first quarter of 2021, the company reported positive top-line data from an investigator-sponsored phase 2 proof-of-concept clinical trial of IMU-838 in primary sclerosing cholangitis which was conducted in collaboration with Mayo Clinic. To date, IMU-838 has been tested in more than 800 individuals and has shown an attractive pharmacokinetic, safety and tolerability profile. IMU-838 is not yet licensed or approved in any country.

About Immunic, Inc.Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company witha pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Immunic is developing three small molecule products: its lead development program,IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORt; and IMU-856 targets the restoration of the intestinal barrier function. For further information, please visit: http://www.imux.com.

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's three development programs and the targeted diseases; the potential for IMU-838 to safely and effectively target diseases; the proof-of-concept study of IMU-838 for the treatment of patients with primary sclerosing cholangitis; the timing of current and future clinical trials; the potential for IMU-838 as a treatment for primary sclerosing cholangitis that may be supported by the investigator-sponsored phase 2 proof-of-concept trial data, and any clinical trials, collaborations and approvals relating to such potential treatment; the nature, strategyand focus of the company; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020, the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the SEC on November 6, 2020, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information

Immunic, Inc. Jessica BreuHead of Investor Relations and Communications+49 89 2080 477 09[emailprotected]

US IR ContactRx Communications GroupPaula Schwartz+1 917 322 2216[emailprotected]

US Media ContactKOGS CommunicationEdna Kaplan+1 781 639 1910[emailprotected]

SOURCE Immunic, Inc.

http://www.immunic-therapeutics.com

Read the original post:
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing...

Biochemistry

Ph.D admission at National Institute for Research in Reproductive Health – Mathrubhumi English

ICMR-National Institute for Research in Reproductive Health; Jehangir Merwanji Street, Parel, Mumbai 400 012, a premier Institute of the Indian Council of Medical Research (ICMR), has invited applications from highly motivated students having consistently good academic record for enrolment in Ph.D. programme of the Institute.

The thrust areas of research include: Fertility Regulation, Infertility and Reproductive Disorders, HIV/STIs/RTIs, Maternal and Child Health, Immunology and Microbiology, Reproductive cancers, Osteoporosis, Genetic Disorders, Stem Cell Biology, Structural Biology, Bioinformatics and Reproductive Toxicology. The Institute is affiliated to the University of Mumbai for the award of Ph.D. degree in Life Sciences, Applied Biology and Biochemistry.

Eligibility: Applicants should be an Indian citizen having Post graduate degree in any branch of Life Sciences (Biochemistry/ Biotechnology/ Microbiology/ Zoology/ Bioinformatics/ Biophysics etc.) or MBBS or MD degree from India with at least 60% or equivalent Cumulative Grade Point Average (CGPA) from higher secondary (10+2) onwards (55% for SC/ST/PWD). Those who have appeared in the academic year 2019-2020 and results are awaited, are also eligible to apply provisionally.

Applicant should have cleared at least one of the following exams: (i) Ph.D. entrance test (PET) conducted by the University of Mumbai in Life Science/ Applied Biology/ Biochemistry/ Microbiology/ Zoology/ Biophysics/ Bioanalytical Sciences/ Molecular Biology (ii) CSIR-UGC NET (JRF or LS) or GATE (Life Sciences/ Biotechnology) (iii) JRF of National agencies such as ICMR/DBT or SET (Life Sciences/Microbiology/Biotechnology/ Biochemistry) (iv) a valid DST-Inspire fellowship.

Age Limit: Upper age limit is 28 years as on 11 January 2021 It is relaxed up to 5 years (33 years) for Women, SC/ST/ PWD/ categories and up to 3 years (31 years) for OBC (NCL). Reservation will be as per the UGC rules followed by University of Mumbai.

Application: Application can be submitted online at the link provided in the detailed Notification at http://www.nirrh.res.in or directly athttp://www.phdappli.nirrh.res.in latest by 25th February 2021.

Application Fees id Rs.300/-. SC/ST/PWD and EWS applicants are exempted from payment of application fees.

Selection: Short-listed applicants will be called for interview. The list of Ph.D. guides (who have vacancy for Ph.D. students in their laboratory) and tentative title of research project to be initiated under them would be given to the shortlisted candidates. Final selection would be based on the performance in the online interview.

Fellowship: Those having JRF of CSIR/UGC/ICMR/DBT can avail fellowship as per the rules of respective funding agency. Non fellowship holders will be provided Institutional fellowship of Rs. 8000/- per month for 2 years only, after successful completion of coursework and Ph.D. proposal presentation. These students are encouraged to seek fellowship from other funding agencies.

For details, visit http://www.nirrh.res.in

Read the rest here:
Ph.D admission at National Institute for Research in Reproductive Health - Mathrubhumi English

Biochemistry

Biochemistry Analysers Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted by the Competitors…

LOS ANGELES, United States:QY Research offers an encyclopedic study of the global Biochemistry Analysers market with holistic insights into vital factors and aspects that impact future market growth. The global Biochemistry Analysers market has been analyzed for the forecast period 2021-2027 and historical period 2015-2020. In order to help players to gain comprehensive understanding of the Global Biochemistry Analysers market and its critical dynamics, the research study provides detailed qualitative and quantitative analysis. Furthermore, readers are offered with complete and thorough research on different regions and segments of the global Biochemistry Analysers market. Almost all industry-specific, microeconomic, and macroeconomic factors influencing the global market growth have been analyzed in the report.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/sample-form/form/2537593/global-biochemistry-analysers-market

The competitive landscape of the global Biochemistry Analysers market is broadly studied in the report with large focus on recent developments, future plans of top players, and key growth strategies adopted by them. The analysts authoring the report have profiled almost every major player of the global Biochemistry Analysers market and thrown light on their crucial business aspects such as production, areas of operation, and product portfolio. All companies analyzed in the report are studied on the basis of vital factors such as market share, market growth, company size, production volume, revenue, and earnings.

Key Players Mentioned in the Global Biochemistry AnalysersMarket Research Report: Thermo Fisher Scientific, Abbott, HORIBA, Siemens Healthcare, Xylem Analytics, Agappe Diagnostics, RMS, MicroLab Instruments, Labindia Instruments

Global Biochemistry Analysers Market by Type: Fully Automated Biochemistry Analyser, Semi Automated Biochemistry Analyser

Global Biochemistry Analysers Market by Application: Hospital and Diagnostic Laboratories, Home Care, Academic and Research Institutes

The report offers great insights into important segments of the global Biochemistry Analysers market while concentrating on their CAGR, market size, market share, and future growth potential. The global Biochemistry Analysers market is mainly segmented according to type of product, application, and region. Each segment in these categories is extensively researched to become familiar with their growth prospects and key trends. Segmental analysis is highly important to identify key growth pockets of a global market. The report provides specific information on the market growth and demand of different products and applications to help players to focus on profitable areas of the global Biochemistry Analysers market.

Key Questions Answered by the Report

Request for customization in Report: https://www.qyresearch.com/customize-request/form/2537593/global-biochemistry-analysers-market

Table of Contents

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Read the rest here:
Biochemistry Analysers Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted by the Competitors...

Biochemistry

IIT Madras researchers find new method to make AIDS drug more effective – Business Today

Researchers at the Indian Institute of Technology, Madras claim to have found a novel way to make HIV/AIDS drugs more effective. The findings of their study, published in Biochemistry, the peer-review Journal of the American Chemical Society, say that introducing electrostatic interaction sites on potential drug molecules can enhance the efficacy of the antiviral drug against the HIV virus. The research was led by Prof. Sanjib Senapati, Department of Biotechnology, IIT Madras, along with research scholars Mohammed Ahsan and Chinmai Pindi.

"Current inhibitors (molecules that bind with the enzyme, thereby making it unavailable to the virus for growth and maturation) that target HIV-1 protease (HIVPR, an essential enzyme that is used by the AIDS virus for growth and maturation), make use of the weak forces of attraction called 'van der Waal's forces' to attach themselves to the protease molecule. Given that these forces are weak, the efficacy of the drug is variable and the virus will soon become resistant to them," Prof. Senapati, says.

The Molecular Dynamics (MD) simulation studies conducted by IIT Madras researchers showed the presence of a strong and asymmetrical electric charge in the active site of the HIVPR. If a drug molecule can be designed with a complementary charge, so that it can bind tightly with this active site through electrostatic attraction, it can permanently deactivate/inhibit the enzyme, they felt.

"Current drugs lack this electrostatic complementarity. This must be investigated because it is well-known that electrostatic forces between molecules are much stronger than van der Waals forces," Prof. Senapati said.

The researchers propose that drug design strategies should embrace both electrostatics and van der Waals interactions to complement the HIVPR active site architecture. Further, the team believes that such compounds will be effective against both wild-type and resistant HIV variants. According to them, it is a paradigm-shifting idea and will offer a whole new approach to the development of drugs for HIV-AIDS.

Prof. Chandra Verma, who has a Ph.D. from Bioinformatics Institute, A*STAR, Singapore, and is not involved in this IIT Madras Research, predicts a bright future for HIV drug development, with such knowledge base.

AIDS is one of the most devastating diseases and is a major cause of death among youth in many parts of the world. Since its outbreak nearly four decades ago, tremendous efforts have been directed towards development of antiretroviral therapies that target different stages in the life cycle of the virus that causes this deadly disease.

Also read: India issues fresh Covid-19 guidelines for travellers from UK, Brazil, South Africa

Also read: BT Business Leaders of TN: Manufacturing, electronics, SaaS can make India $5 trillion economy, say experts

Go here to read the rest:
IIT Madras researchers find new method to make AIDS drug more effective - Business Today

Physiology

Six KSOM departments make top 10 in NIH funding nationally | Keck School of Medicine of USC – USC News

Ophthalmology is No. 1 among med schools for the fourth year in a row, while Preventive Medicine is No. 2

(Photo/iStock)

By Landon Hall

Data on grants awarded from the National Institutes of Health have been released, and the Keck School of Medicine of USC has six departments in the top 10 in their respective fields.

KSOMs Ophthalmology Department is again ranked No. 1 among medical schools in the country. Preventive Medicine, which has covered a wide variety of research topics in recent years and has opened a new COVID-19 research center, is No. 2 in funding.

Rounding out the Top 10 is Neurology at No. 4; Physiology and Neuroscience at No. 5; Otolaryngology at No. 7; and Orthopaedic Surgery at No. 9.

The rankings are based on data compiled by theBlue Ridge Institute for Medical Research.

Were competing better than we used to, said Tom Buchanan, MD, professor of medicine, the Bernard J. Hanley Chair in Medicine and the schools Vice Dean for Research.

He noted how difficult it is to secure an NIH grant, which is based on merit. It takes a good fundamental idea, it takes preliminary data that the idea could be right, and a proposal that is feasible and scientifically very vigorous.

J. Martin Heur, MD, Interim Chair of the Department of Ophthalmology, said: This continues our streak of being ranked No. 1 for four consecutive years and is a testament to the quality of research being carried out in our department. I would like to congratulate everyone in the department for this fantastic achievement.

Preventive Medicine held steady at No. 2.

The Department of Preventive Medicine is once again proud to have gained this re-affirmation of the research strength of its faculty, said Howard Hu, MD, MPH, ScD, the Flora L. Thornton Chair of the Department of Preventive Medicine.Behind the numbers is a deep and abiding commitment to generate the scientific evidence that is essential for optimizing the health of large and diverse urban populations, locally and globally.

Neurology, led by Helena Chui, MD, the Raymond and Betty McCarron Chair in Neurology, rose from No. 9 to No. 4.

The KSOM Department of Neurology is gratified to be ranked No. 4 in NIH funding, Chui said. Over the past decade, USC has made key strategic investments in neuroscience. Our approach has been two-pronged: recruiting topflight talent and supporting our own investigators.

Otolaryngology rose from No. 10 to No. 7. Of course, the research funding itself is not the goal; the goal is discovery, said John Oghalai, MD, Chair of Otolaryngology Head and Neck Surgery, and the Leon J. Tiber and David S. Alpert Chair in Medicine. I am so grateful for the efforts of our faculty, trainees, and staff to understand the basic mechanisms of biology, to discover the mechanisms of disease, and to develop new diagnostics and cures that will help society.

Physiology and Neuroscience, chaired by Berislav V.Zlokovic, MD, PhD, boasts a formidable team of researchers working on some of the most pressing problems in health, including Alzheimers disease.

Jay R. Lieberman, chair of Orthopaedic Surgery, said: Our goal in the Department of Orthopaedic Surgery is to continually innovate to provide our patients with the best care possible, and in our research laboratories we are developing novel treatment regimens for our patients. We have a special interest in translational research focused on stem cell therapies to enhance bone and cartilage repair, muscle and tendon regeneration, and spinal fusion.

To learn more about KSOMs groundbreaking work, visit our Research page.

Link:
Six KSOM departments make top 10 in NIH funding nationally | Keck School of Medicine of USC - USC News